Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
Division of Clinical Research, Research Institute and Hospital of National Cancer Center, Goyang, Korea.
Mult Scler. 2019 Dec;25(14):1942-1945. doi: 10.1177/1352458518810261. Epub 2018 Nov 7.
Alemtuzumab is a potent monoclonal CD52 antibody used to treat patients with multiple sclerosis (MS). However, recent literature reports have described paradoxical activation of B cell-mediated disease within 1 year of the first cycle of alemtuzumab. We raise awareness that severe B cell-mediated disease activation could develop, even after two cycles of alemtuzumab, in some vulnerable MS patients; therefore, individualized therapeutic strategies should be considered in clinical practice. We also propose that a novel regulatory B-cell subset may be a candidate for a predictive biomarker of disease activation in MS patients treated with alemtuzumab.
阿仑单抗是一种强效的 CD52 单克隆抗体，用于治疗多发性硬化症（MS）患者。然而，最近的文献报告描述了在阿仑单抗第一个周期的 1 年内，出现 B 细胞介导的疾病的反常激活。我们提醒注意，在某些脆弱的 MS 患者中，即使经过两个周期的阿仑单抗治疗，也可能会出现严重的 B 细胞介导的疾病激活；因此，在临床实践中应考虑个体化的治疗策略。我们还提出，新型调节性 B 细胞亚群可能是阿仑单抗治疗的 MS 患者疾病激活的预测生物标志物的候选者。
